Ignite Creation Date:
2024-05-06 @ 1:40 PM
Last Modification Date:
2024-10-26 @ 1:17 PM
Study NCT ID:
NCT04080453
Status:
COMPLETED
Last Update Posted:
2024-04-26
First Post:
2019-09-03
Brief Title:
Pro-inflammatory Role of Blood Platelets in Critically Ill Patients With Septic Shock
Sponsor:
University Hospital Bordeaux
Organization:
University Hospital Bordeaux
Study Overview
Official Title:
Pro-inflammatory Role of Blood Platelets in Critically Ill Patients With Septic Shock an Observational Study
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PLAQSIS
Brief Summary:
Blood platelets play a major role in the inflammatory response A dysregulation of platelets activation may be one of the contributors to tissue damage in critically ill patients with septic shock The main objective of this study is to compare platelet activation markers levels including plasma concentration in CD154 beta thromboglobulin platelet factor 4 platelet microparticles soluble CD62 RANTES GRO-alpha and HMGB-1 at the early phase of a septic shock and a systemic inflammatory response syndrome SIRS
Detailed Description:
Sepsis is defined as life-threatening organ dysfunction due to dysregulated host response to infection which can lead to many failures of vital organs kidneys lungs liver in critically ill patients It is accompanied at an early phase by both a proinflammatory and procoagulant state generating many platelet activators Given their essential role in the inflammatory response a dysregulation of platelets activation may be one of the contributors to tissue damage To determine if platelet activation contribute to deregulation of the inflammatory response of the host in sepsis the main objective of this study is to compare platelet activation markers levels of patients with septic shock and after major surgery Plasma concentration in CD154 beta thromboglobulin platelet factor 4 platelet microparticles soluble CD62 RANTES GRO-alpha HMGB-1 monocyte Dnases signal circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion Day 0 Day 1 and Day 5
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None